144 related articles for article (PubMed ID: 36991305)
21. Quantitative volumetric assessment of baseline enhancing tumor volume as an imaging biomarker predicts overall survival in patients with glioblastoma.
Auer TA; Della Seta M; Collettini F; Chapiro J; Zschaeck S; Ghadjar P; Badakhshi H; Florange J; Hamm B; Budach V; Kaul D
Acta Radiol; 2021 Sep; 62(9):1200-1207. PubMed ID: 32938221
[TBL] [Abstract][Full Text] [Related]
22. Survival impact of the time gap between surgery and chemo-radiotherapy in Glioblastoma patients.
Zur I; Tzuk-Shina T; Guriel M; Eran A; Kaidar-Person O
Sci Rep; 2020 Jun; 10(1):9595. PubMed ID: 32533126
[TBL] [Abstract][Full Text] [Related]
23. Determining a cut-off residual tumor volume threshold for patients with newly diagnosed glioblastoma treated with temozolomide chemoradiotherapy: A multicenter cohort study.
Woo PYM; Ho JMK; Tse TPK; Lam SW; Mak CHK; Chan DTM; Lee MWY; Wong ST; Chan KY; Poon WS
J Clin Neurosci; 2019 May; 63():134-141. PubMed ID: 30712777
[TBL] [Abstract][Full Text] [Related]
24. Concurrent chemoradiotherapy versus radiotherapy alone for "biopsy-only" glioblastoma multiforme.
Kole AJ; Park HS; Yeboa DN; Rutter CE; Corso CD; Aneja S; Lester-Coll NH; Mancini BR; Knisely JP; Yu JB
Cancer; 2016 Aug; 122(15):2364-70. PubMed ID: 27172136
[TBL] [Abstract][Full Text] [Related]
25. Dynamic susceptibility contrast MRI measures of relative cerebral blood volume as a prognostic marker for overall survival in recurrent glioblastoma: results from the ACRIN 6677/RTOG 0625 multicenter trial.
Schmainda KM; Zhang Z; Prah M; Snyder BS; Gilbert MR; Sorensen AG; Barboriak DP; Boxerman JL
Neuro Oncol; 2015 Aug; 17(8):1148-56. PubMed ID: 25646027
[TBL] [Abstract][Full Text] [Related]
26. The predictive value of absolute lymphocyte counts on tumor progression and pseudoprogression in patients with glioblastoma.
Xi J; Hassan B; Katumba RGN; Khaddour K; Govindan A; Luo J; Huang J; Campian JL
BMC Cancer; 2021 Mar; 21(1):285. PubMed ID: 33726710
[TBL] [Abstract][Full Text] [Related]
27. Prognostic Prediction Based on Dynamic Contrast-Enhanced MRI and Dynamic Susceptibility Contrast-Enhanced MRI Parameters from Non-Enhancing, T2-High-Signal-Intensity Lesions in Patients with Glioblastoma.
Jo SW; Choi SH; Lee EJ; Yoo RE; Kang KM; Yun TJ; Kim JH; Sohn CH
Korean J Radiol; 2021 Aug; 22(8):1369-1378. PubMed ID: 33987994
[TBL] [Abstract][Full Text] [Related]
28. Quantitative T1-mapping detects cloudy-enhancing tumor compartments predicting outcome of patients with glioblastoma.
Müller A; Jurcoane A; Kebir S; Ditter P; Schrader F; Herrlinger U; Tzaridis T; Mädler B; Schild HH; Glas M; Hattingen E
Cancer Med; 2017 Jan; 6(1):89-99. PubMed ID: 27891815
[TBL] [Abstract][Full Text] [Related]
29. Prediction of Response to Concurrent Chemoradiotherapy with Temozolomide in Glioblastoma: Application of Immediate Post-Operative Dynamic Susceptibility Contrast and Diffusion-Weighted MR Imaging.
Lee EK; Choi SH; Yun TJ; Kang KM; Kim TM; Lee SH; Park CK; Park SH; Kim IH
Korean J Radiol; 2015; 16(6):1341-8. PubMed ID: 26576125
[TBL] [Abstract][Full Text] [Related]
30. MRI assessment of relapsed glioblastoma during treatment with bevacizumab: volumetric measurement of enhanced and FLAIR lesions for evaluation of response and progression--a pilot study.
Pichler J; Pachinger C; Pelz M; Kleiser R
Eur J Radiol; 2013 May; 82(5):e240-5. PubMed ID: 23399039
[TBL] [Abstract][Full Text] [Related]
31. Prediction of survival in patients affected by glioblastoma: histogram analysis of perfusion MRI.
Romano A; Pasquini L; Di Napoli A; Tavanti F; Boellis A; Rossi Espagnet MC; Minniti G; Bozzao A
J Neurooncol; 2018 Sep; 139(2):455-460. PubMed ID: 29721752
[TBL] [Abstract][Full Text] [Related]
32. Apparent diffusion coefficient and tumor volume measurements help stratify progression-free survival of bevacizumab-treated patients with recurrent glioblastoma multiforme.
Buemi F; Guzzardi G; Del Sette B; Sponghini AP; Matheoud R; Soligo E; Trisoglio A; Carriero A; Stecco A
Neuroradiol J; 2019 Aug; 32(4):241-249. PubMed ID: 31066622
[TBL] [Abstract][Full Text] [Related]
33. Development and Validation of a MRI-Based Radiomics Prognostic Classifier in Patients with Primary Glioblastoma Multiforme.
Chen X; Fang M; Dong D; Liu L; Xu X; Wei X; Jiang X; Qin L; Liu Z
Acad Radiol; 2019 Oct; 26(10):1292-1300. PubMed ID: 30660472
[TBL] [Abstract][Full Text] [Related]
34. Dynamic Contrast-Enhanced MR Imaging of Nonenhancing T2 High-Signal-Intensity Lesions in Baseline and Posttreatment Glioblastoma: Temporal Change and Prognostic Value.
Hwang I; Choi SH; Park CK; Kim TM; Park SH; Won JK; Kim IH; Lee ST; Yoo RE; Kang KM; Yun TJ; Kim JH; Sohn CH
AJNR Am J Neuroradiol; 2020 Jan; 41(1):49-56. PubMed ID: 31806595
[TBL] [Abstract][Full Text] [Related]
35. Residual tumor volume versus extent of resection: predictors of survival after surgery for glioblastoma.
Grabowski MM; Recinos PF; Nowacki AS; Schroeder JL; Angelov L; Barnett GH; Vogelbaum MA
J Neurosurg; 2014 Nov; 121(5):1115-23. PubMed ID: 25192475
[TBL] [Abstract][Full Text] [Related]
36. Definitive chemoradiation at high volume facilities is associated with improved survival in glioblastoma.
Haque W; Verma V; Butler EB; Teh BS
J Neurooncol; 2017 Oct; 135(1):173-181. PubMed ID: 28687924
[TBL] [Abstract][Full Text] [Related]
37. Response Assessment in Neuro-Oncology criteria, contrast enhancement and perfusion MRI for assessing progression in glioblastoma.
Tensaouti F; Khalifa J; Lusque A; Plas B; Lotterie JA; Berry I; Laprie A; Cohen-Jonathan Moyal E; Lubrano V
Neuroradiology; 2017 Oct; 59(10):1013-1020. PubMed ID: 28842741
[TBL] [Abstract][Full Text] [Related]
38. Glioblastoma management in the temozolomide era: have we improved outcome?
Lwin Z; MacFadden D; Al-Zahrani A; Atenafu E; Miller BA; Sahgal A; Menard C; Laperriere N; Mason WP
J Neurooncol; 2013 Nov; 115(2):303-10. PubMed ID: 23979682
[TBL] [Abstract][Full Text] [Related]
39. Prognosis prediction of measurable enhancing lesion after completion of standard concomitant chemoradiotherapy and adjuvant temozolomide in glioblastoma patients: application of dynamic susceptibility contrast perfusion and diffusion-weighted imaging.
Kim JH; Choi SH; Ryoo I; Yun TJ; Kim TM; Lee SH; Park CK; Kim JH; Sohn CH; Park SH; Kim IH
PLoS One; 2014; 9(11):e113587. PubMed ID: 25419975
[TBL] [Abstract][Full Text] [Related]
40. Phase I study of hypofractionated intensity modulated radiation therapy with concurrent and adjuvant temozolomide in patients with glioblastoma multiforme.
Jastaniyah N; Murtha A; Pervez N; Le D; Roa W; Patel S; Mackenzie M; Fulton D; Field C; Ghosh S; Fallone G; Abdulkarim B
Radiat Oncol; 2013 Feb; 8():38. PubMed ID: 23425509
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
